Compare MBIN & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | XERS |
|---|---|---|
| Founded | 1990 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.8B |
| IPO Year | 2017 | 2021 |
| Metric | MBIN | XERS |
|---|---|---|
| Price | $49.51 | $17.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $67.00 | $17.29 |
| AVG Volume (30 Days) | 115.6K | ★ 3.0M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ 4.79 | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $10.52 | $37.58 |
| Revenue Next Year | $3.15 | $31.16 |
| P/E Ratio | $10.44 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $30.95 | $5.25 |
| 52 Week High | $56.87 | $17.28 |
| Indicator | MBIN | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 81.73 |
| Support Level | $47.81 | $5.90 |
| Resistance Level | $51.01 | N/A |
| Average True Range (ATR) | 1.40 | 0.71 |
| MACD | -0.36 | 0.20 |
| Stochastic Oscillator | 3.97 | 95.37 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.